Get started
Author

Kat Kwiatkowski

ORCID: 0000-0002-7019-2488
Observed ORCID: 0000-0002-7019-2488
OpenAlex ID: A5086422029
Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?
2013 · Kat Kwiatkowski, Kathryn Coe, et al. · Cancer · 248
PDF
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples
2021 · Scott A. Tomlins, Daniel H. Hovelson, et al. · JCO Precision Oncology · 37
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
2023 · Scott A. Tomlins, Nickolay A. Khazanov, et al. · Communications Medicine · 31
PDF
Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test
2021 · Scott A. Tomlins, Daniel H. Hovelson, et al. · Journal of Molecular Diagnostics · 24
Clinical performance of the CytoScan Dx Assay in diagnosing developmental delay/intellectual disability
2015 · Rolph Pfundt, Kat Kwiatkowski, et al. · Genetics in Medicine · 13
PDF
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al. · Cancer Research Communications · 12
PDF
Evaluation of a predictive biomarker for antibody drug conjugates (ADCs).
2024 · Sachdev P. Thomas, Laurel A. Habel, et al. · Journal of Clinical Oncology · 4
Clinical utility of chromosomal microarray analysis in the diagnosis and management of monosomy 7 mosaicism
2014 · Alka Chaubey nee Dwivedi, Michael J Lyons, et al. · Molecular Cytogenetics · 3
PDF
Abstract 2171: A multivariate biomarker predicts sacituzumab govitecan response in solid tumors
2023 · Nickolay A. Khazanov, Laura E. Lamb, et al. · Cancer Research · 2
Development and validation of a tumor tissue based multivariate biomarker for predicting angiogenesis inhibitor clinical benefit in renal cell carcinoma (RCC).
2024 · Sachdev P. Thomas, Ulka N. Vaishampayan, et al. · Journal of Clinical Oncology · 1
PDF
Abstract 968: Evaluation of Her2 RNA expression as a potential predictive biomarker for anti-Her2 therapy
2023 · Laura E. Lamb, Nickolay A. Khazanov, et al. · Cancer Research · 1
PCR-based comprehensive genomic profiling (PCR-CGP): Feasibility from >20,000 tumor tissue specimens (TTS) and predicted impact on actionable biomarker identification versus hybrid capture (H)-CGP and plasma (P)-CGP.
2020 · Dan Rhodes, Daniel H Hovelson, et al. · Journal of Clinical Oncology · 1
No-cost next generation sequencing of advanced cancer patients within the Strata Precision Oncology Network supports clinical trial enrollment.
2019 · Marc Ryan Matrana, Scott A. Tomlins, et al. · Journal of Clinical Oncology · 1
An observational study profiling biospecimens from 10,000 metastatic prostate cancer (mPCa) patients to screen for molecular alterations.
2018 · Won Kim, Kat Kwiatkowski, et al. · Journal of Clinical Oncology · 1
PP01.106 Validation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab Monotherapy Benefit in First Line (1L) Non-small cell lung cancer (NSCLC)
2024 · Brandi Oakley, Justin Moon, et al. · Journal of Thoracic Oncology
PDF
Abstract PO1-14-04: A multivariate biomarker to guide antibody-drug conjugate selection and provide insight on response differences across breast cancer subtypes
2024 · Laura Lamb, Jonathan Mowers, et al. · Cancer Research
Development and application of a precision cell-free DNA (cfDNA) minimal residual disease (MRD) test to enable optimized treatment selection in patients with genitourinary (GU) cancers.
2024 · Derrian Cooley, Ulka N. Vaishampayan, et al. · Journal of Clinical Oncology
FIGURE 4 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Data S2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Table S7 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Figure S1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
PDF
Supplementary Figure S6 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Figure S2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Works count: 91
Citation count: 379
H-index: 6
I10-index: 6
Year
Topic
Type